Patents Examined by Yong S. Chong
  • Patent number: 11938150
    Abstract: The present invention provides a method of treating frontotemporal dementia, or a childhood genetic neurodegenerative disease such as Ataxia Telangiectasia (A-T), or neurodegenerative diseases such as Parkinson's disease or neuropsychiatric diseases comprising administering to a subject in need thereof an effective amount of chlorite composition, such as sodium chlorite. The present invention thereby provides a method of modulating the immune system in a subject in need thereof. Described herein are methods of administration and treatment.
    Type: Grant
    Filed: January 10, 2023
    Date of Patent: March 26, 2024
    Assignees: NEUVIVO, INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Vernon A. Norviel, Michael S. McGrath
  • Patent number: 11938148
    Abstract: The present invention provides a method of treating frontotemporal dementia, or a childhood genetic neurodegenerative disease such as Ataxia Telangiectasia (A-T), or neurodegenerative diseases such as Parkinson's disease or neuropsychiatric diseases comprising administering to a subject in need thereof an effective amount of chlorite composition, such as sodium chlorite. The present invention thereby provides a method of modulating the immune system in a subject in need thereof. Described herein are methods of administration and treatment.
    Type: Grant
    Filed: January 10, 2023
    Date of Patent: March 26, 2024
    Assignees: NEUVIVO, INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Vernon A. Norviel, Michael S. McGrath
  • Patent number: 11938147
    Abstract: The present invention provides a method of treating frontotemporal dementia, or a childhood genetic neurodegenerative disease such as Ataxia Telangiectasia (A-T), or neurodegenerative diseases such as Parkinson's disease or neuropsychiatric diseases comprising administering to a subject in need thereof an effective amount of chlorite composition, such as sodium chlorite. The present invention thereby provides a method of modulating the immune system in a subject in need thereof. Described herein are methods of administration and treatment.
    Type: Grant
    Filed: August 30, 2022
    Date of Patent: March 26, 2024
    Assignees: NEUVIVO, INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Vernon A. Norviel, Michael S. McGrath
  • Patent number: 11938149
    Abstract: The present invention provides a method of treating frontotemporal dementia, or a childhood genetic neurodegenerative disease such as Ataxia Telangiectasia (A-T), or neurodegenerative diseases such as Parkinson's disease or neuropsychiatric diseases comprising administering to a subject in need thereof an effective amount of chlorite composition, such as sodium chlorite. The present invention thereby provides a method of modulating the immune system in a subject in need thereof. Described herein are methods of administration and treatment.
    Type: Grant
    Filed: January 10, 2023
    Date of Patent: March 26, 2024
    Assignees: NEUVIVO, INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Vernon A. Norviel, Michael S. McGrath
  • Patent number: 11931338
    Abstract: Disclosed are novel nitrilated psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The compounds may be produced by reacting a reactant psilocybin derivative with a nitrile-group containing compound.
    Type: Grant
    Filed: September 16, 2022
    Date of Patent: March 19, 2024
    Assignee: Enveric Biosciences Canada Inc.
    Inventors: Jillian M. Hagel, Peter J. Facchini, Chang-Chun Ling
  • Patent number: 11931330
    Abstract: A composition for promoting mitochondrial biogenesis includes an effective amount of an azelaic acid or a pharmaceutically acceptable salt thereof as an active ingredient. Azelaic acid, which is a compound mainly contained in cereals and natural products has the advantage of no or little side effects, and induces mitochondrial autophagy and mitochondrial DNA synthesis in cells, thereby having activity of increasing mitochondrial density. Therefore, azelaic acid can be used for the treatment of mitochondrial dysfunction-associated disease caused by the failure of homeostasis control of the mitochondria, for example, mitochondrial activity or the decrease in the number of mitochondria.
    Type: Grant
    Filed: September 2, 2020
    Date of Patent: March 19, 2024
    Assignee: Korea University Research and Business Foundation
    Inventor: Sung-Joon Lee
  • Patent number: 11905254
    Abstract: A 1-(3-chlorobenzylideneamino)-5,5-diphenylimidazolidine-2,4-dione compound, its synthesis, and its use as an antimicrobial agent.
    Type: Grant
    Filed: October 17, 2023
    Date of Patent: February 20, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
  • Patent number: 11896568
    Abstract: Pharmaceutical compositions, kits and methods for treating tumors such as glioma and cancers such as leukemia with (R)-2-hydroxyglutarate (R-2HG) are provided, along with therapeutic regimens including treatment of a patient suffering from glioma or leukemia with a MYC-signaling inhibitor followed by or cotemporaneous with treatment with R-2HG, and optionally other chemotherapeutic agents.
    Type: Grant
    Filed: October 14, 2021
    Date of Patent: February 13, 2024
    Assignee: University of Cincinnati
    Inventors: Jianjun Chen, Rui Su
  • Patent number: 11891374
    Abstract: Embodiments of the present invention generally concern pharmaceutical formulations and compositions and methods for using the pharmaceutical formulations and compositions which comprise derivatives of benzimidazole compounds, their racemic mixtures, their enantiomers, their complexes, their salts, and combinations thereof which have been found to be novel agonists of imidizoline receptors with surprising life extending efficacies due to their geroprotective (anti-geriatric) actions on pathologies associated with the aging processes in humans and animals.
    Type: Grant
    Filed: January 17, 2020
    Date of Patent: February 6, 2024
    Inventors: Boris Farber, Artur Viktorovich Martynov, Serhii Ivanovych Merzlikin
  • Patent number: 11878007
    Abstract: In various embodiments of the present disclosure, compositions exhibiting metabolism boosting effect are described. In various examples, compositions comprise a synergistic combination of at least one plant, root, seed, or fruit material, or extract thereof, or bioactive therefrom; at least one vitamin, essential trace mineral, or enzyme or vitamin cofactor; at least one amino acid; and at least one antioxidant. In various aspects, metabolism enhancing compositions are formulated as loose powders filled into capsules as orally administered dietary supplements. In various embodiments, compositions of the present disclosure are used to treat metabolic syndrome in subjects expressing symptoms thereof.
    Type: Grant
    Filed: August 10, 2022
    Date of Patent: January 23, 2024
    Assignee: RED MOUNTAIN MED SPA, LLC
    Inventor: Suzanne Bentz
  • Patent number: 11877992
    Abstract: A method of treating dyslexia and/or other learning disorders comprises administering at least one gamma-hydroxybutyrate salt.
    Type: Grant
    Filed: June 7, 2022
    Date of Patent: January 23, 2024
    Inventor: Kelly Kathleen Spinelli
  • Patent number: 11877993
    Abstract: A method of treating PTSD and/or other psychological disorders comprises administering at least one gamma-hydroxybutyrate salt.
    Type: Grant
    Filed: June 23, 2022
    Date of Patent: January 23, 2024
    Inventor: Kelly Kathleen Spinelli
  • Patent number: 11872227
    Abstract: The present disclosure relates to a pharmaceutical combination comprising (a) a histone deacetylase 6 inhibitor and (b) an aurora kinase inhibitor, including combined preparations and pharmaceutical compositions thereof; uses of such combination in the treatment or prevention of cancer; and methods of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of such combination.
    Type: Grant
    Filed: May 10, 2022
    Date of Patent: January 16, 2024
    Assignee: ACETYLON PHARMACEUTICALS, INC.
    Inventors: Brian North, Steven Quayle
  • Patent number: 11865126
    Abstract: The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat anxiety disorders, eating disorders, and headache disorders.
    Type: Grant
    Filed: June 15, 2023
    Date of Patent: January 9, 2024
    Assignee: Compass Pathfinder Limited
    Inventors: Derek John Londesbrough, Christopher Brown, Julian Scott Northen, Gillian Moore, Hemant Kashinath Patil, David E. Nichols, Megan Croal, Hans Åke Eriksson, George Goldsmith, Molly Tabitha Hickey, Shaun Hurley, Ekaterina Malievskaia, Lindsey Marwood, Drummond E-Wen Joe Mcculloch, Laurie Emma Medhurst, Nathan Poulsen, Aslihan Selimbeyoglu, Anaïs Soula, Amanda Tan Shuxiang, Manon Cecile Elisabeth Veraart, Tobias Patrick Whelan, Lars Christian Wilde, Stephen Wright
  • Patent number: 11865180
    Abstract: The present invention relates to novel oral spray formulations of Levothyroxine. Further the invention also describes process for preparing such formulations.
    Type: Grant
    Filed: April 28, 2022
    Date of Patent: January 9, 2024
    Assignee: LEIUTIS PHARMACEUTICALS LLP
    Inventors: Kocherlakota Chandrashekhar, Banda Nagaraju
  • Patent number: 11850250
    Abstract: Disclosed is a use of homoharringtonine (HHT) in preparation of a drug against betacoronavirus infection, a use of homoharringtonine in preparation of a betacoronavirus replication inhibitor in human, and a formulation and a method for treating a disease caused by betacoronavirus. Through research, the HHT is found to not only have a good inhibitory effect on the first step of protein synthesis, but also have an unexpected inhibitory effect on each step of protein synthesis elongation, and can better inhibit the synthesis of long proteins. Because betacoronaviruses have longer ORFs and are more sensitive to the HHT, the HHT has a better replication inhibition effect on the betacoronaviruses, thus providing a feasible solution for controlling the replication of coronaviruses. The effects of the HHT on treating diseases caused by the betacoronaviruses including SARS-CoV-2 are confirmed for the first time by cell experiments and animal models.
    Type: Grant
    Filed: August 20, 2021
    Date of Patent: December 26, 2023
    Assignee: HANGZHOU MINSHENG PHARMACEUTICAL CO., LTD.
    Inventors: Chungl Wu, Haijun Wen
  • Patent number: 11850242
    Abstract: Compositions suitable for oral use (e.g., oral thin film) containing various excipients and a combination of melatonin, caryophyllene, GABA, L-theanine, and vitamin B6. Methods of using the composition, e.g., in the treatment of a sleeping disorder, as well as methods of manufacturing the composition are also included.
    Type: Grant
    Filed: April 25, 2022
    Date of Patent: December 26, 2023
    Inventor: Jose Bernardo
  • Patent number: 11834391
    Abstract: The present invention provides compounds that have antimalarial activity. More in particular, the present invention provides novel compounds that are analogues of pantothenamides. The pantothenamide analogues of this invention have particularly low IC50 values against the asexual blood stages and gametocytes of malaria parasites. Furthermore, the pantothenamide analogues of this invention are characterized by low hepatic metabolism. Therefore, pantothenamide analogues of the invention are particularly suitable for use in therapeutic and/or prophylactic treatment of protozoan infections in a human or animal subject in need thereof. The invention further provides pharmaceutical formulations comprising the pantothenamide analogues as well as the therapeutic and/or prophylactic uses of the pantothenamide analogues and pharmaceutical formulations comprising them.
    Type: Grant
    Filed: January 20, 2023
    Date of Patent: December 5, 2023
    Assignee: MMV MEDICINES FOR MALARIA VENTURE
    Inventors: Josephus Schalkwijk, Pedro Harold Han Hermkens, Koen Jakob Dechering, Roger Victor Bonnert
  • Patent number: 11793781
    Abstract: The present specification provides RXR agonist compounds, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such RXR agonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection.
    Type: Grant
    Filed: January 27, 2022
    Date of Patent: October 24, 2023
    Assignees: Io Therapeutics, Inc., Trustees of Dartmouth College
    Inventors: Roshantha A. Chandraratna, Ethan Dmitrovsky, Elizabeth Nowak, Randolph Noelle
  • Patent number: 11767289
    Abstract: Methods and compositions for pest control, and more particularly for control of ants, e.g., of the subfamily Myrmicinae, using tyramides.
    Type: Grant
    Filed: January 30, 2017
    Date of Patent: September 26, 2023
    Assignees: United States of America, as represented by the Secretary of Agriculture, THE VMI FOUNDATION
    Inventors: Tappey H. Jones, Robert Kenneth Vander Meer